Advertisement

Rheumatology International

, Volume 39, Issue 10, pp 1777–1781 | Cite as

Prevalence of other connective tissue diseases in idiopathic inflammatory myopathies

  • Adam Maundrell
  • Susanna Proudman
  • Vidya LimayeEmail author
Observational Research
  • 114 Downloads

Abstract

We sought to determine the prevalence of additional connective tissue diseases (CTDs) in patients with idiopathic inflammatory myopathies (IIM), and to study the muscle biopsy patterns in various clinico-serologic subsets of myositis. We undertook a retrospective cohort study of 648 patients with a histological diagnosis of IIM. The following was determined from the South Australian Myositis Database: presence of associated CTDs, histological details and presence of myositis-specific (MSA) or myositis-associated (MAA) antibodies. Among patients with IIM, a significantly greater proportion had systemic sclerosis 32/648 (4.9%) than mixed connective tissue disease (12/648, p = 0.003), primary Sjogren’s syndrome (12/648, p = 0.003), systemic lupus erythematosus (10/648, p < 0.001) or rheumatoid arthritis (6/648, p = 0.0001). Polymyositis was the most common IIM diagnosis regardless of the presence or absence of CTD. MSA/MAA was more commonly detected in those with systemic sclerosis than those with IIM alone (OR 5.35, p < 0.005). The higher prevalence of SSc (compared with other CTDs) in IIM, together with the more frequent detection of autoantibodies in this group, suggests that these conditions may be linked.

Keywords

Myositis Systemic sclerosis Scleroderma Myositis overlap Connective tissue disease 

Notes

Acknowledgements

The authors are grateful to the Department of Anatomical Pathology, SA Pathology and to all patients and physicians who have supported the South Australian Myositis Database.

Funding

No specific funding was obtained for this research.

Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest and no disclosures.

Human and animal rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Limaye VS, Blumbergs P, Roberts-Thomson PJ (2009) Idiopathic inflammatory myopathies. Intern Med J 39:179–190CrossRefGoogle Scholar
  2. 2.
    Ghirardello A, Bassi N, Palma L, Borella E, Domeneghetti M, Punzi L et al (2013) Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep 15:335CrossRefGoogle Scholar
  3. 3.
    Gunawardena H, Betteridge ZE, McHugh NJ (2009) Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 48:607–612CrossRefGoogle Scholar
  4. 4.
    Tansley S, Gunawardena H (2014) The evolving spectrum of polymyositis and dermatomyositis—moving towards clinicoserological syndromes: a critical review. Clin Rev Allergy Immunol 47:264–273CrossRefGoogle Scholar
  5. 5.
    Limaye VS, Lester S, Bardy P, Thompson P, Cox S, Blumbergs P et al (2012) A three-way interplay of DR4, autoantibodies and synovitis in biopsy-proven idiopathic inflammatory myositis. Rheumatol Int 32:611–619CrossRefGoogle Scholar
  6. 6.
    Mimura Y, Ihn H, Jinnin M et al (2005) Clinical and laboratory features of scleroderma patients developing skeletal myopathy. Clin Rheumatol 24:99–102CrossRefGoogle Scholar
  7. 7.
    Balbir-Gurman A, Braun-Moscovici Y (2011) Scleroderma overlap syndrome. Isr Med Assoc J 13:14–20Google Scholar
  8. 8.
    Muangchan C, Canadian Scleroderma Research Group, Baron M, Pope J (2013) The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis A systematic review. J Rheumatol 40:1545–1556CrossRefGoogle Scholar
  9. 9.
    Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, Jarzabek-Chorzelska M, Targoff IN, Blaszczyk-Kostanecka M et al (1997) Clinical, serologic and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 40:1257–1266CrossRefGoogle Scholar
  10. 10.
    Vansca A, Gergely L, Ponyi A, Lakos G, Nemeth J, Szodoray P et al (2010) Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: relevance for clinical classification: retrospective study of 169 patients. Jt Bone Spine 77:125–130CrossRefGoogle Scholar
  11. 11.
    Dalakas MC (2011) Pathophysiology of inflammatory and autoimmune myopathies. Presse Med 40:e237–e247CrossRefGoogle Scholar
  12. 12.
    Mastaglia FL, Phillips BA (2002) Idiopathic inflammatory myopathies, epidemiology, classification and diagnostic criteria. Rheum Dis Clin N Am 28:723–741CrossRefGoogle Scholar
  13. 13.
    Hochberg MC, Feldman D, Stevens MB (1986) Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum 15:168–178CrossRefGoogle Scholar
  14. 14.
    Ramesha KN, Kuruvilla A, Sarma PS, Radhakrishnan VV (2010) Clinical, electrophysiologic and histopathologic profile, and outcome in idiopathic inflammatory myositis: an analysis of 68 cases. Ann Indian Acad Neurol 13:250–256CrossRefGoogle Scholar
  15. 15.
    Aguila LA, Lopes MR, Pretti FZ, Sampaio-Barros PD, Carlos de Souza FH, Borba EF et al (2014) Clinical and laboratory features of overlap syndromes of idiopathic inflammatory myopathies associated with systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis. Clin Rheumatol 33:1093–1098CrossRefGoogle Scholar
  16. 16.
    Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies, Analysis of 100 French Canadian patients. Medicine 84:231–249CrossRefGoogle Scholar
  17. 17.
    Koschik RW, Fertig N, Lucas MR, Domsic RT, Medsger TA Jr (2012) Anti-PM-Scl antibody in patients with systemic sclerosis. Clin Exp Rheumatol 30:S12–S16Google Scholar
  18. 18.
    Schulte-Pelkum J, Fritzler M, Mahler M (2009) Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 8:632–637CrossRefGoogle Scholar
  19. 19.
    Cooley HM, Melny BJ, Gleeson R, Greco T, Kay TW (1999) Clinical and serological associations of anti-Ku antibody. J Rheumatol 26:563Google Scholar
  20. 20.
    Rozman B, Cucnik S, Sodin-Semrl S, Czirjak L, Varju C, Distler O et al (2008) Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study. Ann Rheum Dis 67:1282–1286CrossRefGoogle Scholar
  21. 21.
    Suzuki S, Yonekawa T, Kuwana M, Hayashi Y, Okazaki Y, Kawaguchi Y et al (2014) Clinical and histological findings associated with autoantibodies detected by RNA immunoprecipitation in inflammatory myopathies. J Neuroimmunol 274:202–208CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Adam Maundrell
    • 1
  • Susanna Proudman
    • 2
    • 3
  • Vidya Limaye
    • 2
    • 3
    Email author
  1. 1.Rheumatologist, Rheumatology TasmaniaHobartAustralia
  2. 2.Rheumatology DepartmentRoyal Adelaide HospitalAdelaideAustralia
  3. 3.Discipline of MedicineUniversity of AdelaideAdelaideAustralia

Personalised recommendations